Skip to main content
DongKook Life Science Co., Ltd. logo

DongKook Life Science Co., Ltd. — Investor Relations & Filings

Ticker · 303810 ISIN · KR7303810006 KO Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2026-04-09 Director's Dealing
Country KR South Korea
Listing KO 303810

About DongKook Life Science Co., Ltd.

http://www.dkls.co.kr/eng/

DongKook Life Science Co., Ltd. is a specialized pharmaceutical company focused on diagnostic medicine and medical devices. The company develops, manufactures, and supplies a range of products with a core specialization in contrast media for medical imaging modalities such as X-ray and magnetic resonance imaging (MRI). In addition to its diagnostic pharmaceuticals, the company is involved in developing AI-powered medical technology. With a strong emphasis on research and development, DongKook Life Science focuses on technical innovation and the creation of new products, having successfully localized key diagnostic medicines for the market. The company serves a global customer base across numerous countries.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean ‘임원ㆍ주요주주 특정증권등 소유상황보고서’ filed with the Securities and Futures Commission and Korea Exchange, detailing an officer’s holdings and transactions in the company’s shares. This matches a report of personal share transactions by a company director (insider dealing). Therefore, it should be classified as Director's Dealing (DIRS).
2026-04-09 Korean
기업설명회(IR)개최
Regulatory Filings
2026-04-07 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal notification to the Financial Services Commission/Korea Exchange regarding the appointment, reappointment, dismissal, or mid-term resignation of outside directors. It details the changes in board composition (number of outside directors before/after, names, terms). This clearly falls under announcements of changes in the company’s board of directors. Therefore, it is classified as Board/Management Information (MANG).
2026-03-23 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report detailing the results of a General Meeting of Shareholders (AGM). It includes specific sections on voting results for agenda items (financial statement approval, director appointments, etc.), dividend resolutions, and board composition. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-03-20 Korean
[기재정정]사업보고서 (2025.12)
Regulatory Filings Classification · 1% confidence The document is a 'Correction Report' (정정신고) for a 'Business Report' (사업보고서) filed by Dongkook Life Science. It details specific corrections made to the notes of the financial statements (III. 재무에 관한 사항 5. 재무제표 주석). Since this is a formal regulatory filing correcting a previously submitted annual financial report, it falls under the category of regulatory filings that provide updates or corrections to financial disclosures.
2026-03-13 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for Dongkook Life Science Co., Ltd. for the fiscal year 2025 (2025.01.01-2025.12.31). It contains comprehensive information including company overview, history, capital changes, and detailed business descriptions. In the context of Korean corporate filings, the 'Business Report' (사업보고서) is the equivalent of the US 10-K annual report, as it is the primary annual disclosure document filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). FY 2025
2026-03-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.